Adelabio
3 known investors
Adela develops blood-based diagnostic tests that analyze cell-free DNA using whole methylome analysis to detect and monitor cancer. It serves clinicians and biopharma partners with applications including early multi-cancer detection, minimal residual disease detection, and immunotherapy response monitoring.
BiotechDigital HealthHealthtech
Investors Β· 3
Frequently asked questions
- What does Adelabio do?
- Adela develops blood-based diagnostic tests that analyze cell-free DNA using whole methylome analysis to detect and monitor cancer. It serves clinicians and biopharma partners with applications including early multi-cancer detection, minimal residual disease detection, and immunotherapy response monitoring.
- Who are Adelabio's investors?
- Adelabio's investors include Decheng Capital, F-Prime Capital Partners, OrbiMed.